GLP-1s and Sleep Apnea

This is one of the clearest benefit stories in the whole field, and it comes with a practical trap that catches a lot of people.

What the trial showed

SURMOUNT-OSA, published in the NEJM in 2024, randomised adults with obesity and moderate-to-severe obstructive sleep apnea — both those using CPAP and those not — to tirzepatide or placebo over 52 weeks.

The primary measure was the apnea-hypopnea index, the number of breathing interruptions per hour of sleep. Tirzepatide reduced it substantially against placebo, by a margin large enough to move many participants down a severity category, and a meaningful proportion reached the threshold that would be considered remission. Sleep-related quality of life and blood pressure improved too.

Following that trial, tirzepatide marketed as Zepbound received an approved indication for moderate-to-severe obstructive sleep apnea in adults with obesity — the first drug approved for the condition.

Why weight loss works on apnea

Obstructive sleep apnea is a mechanical problem: the upper airway collapses during sleep. Fat deposition around the neck and tongue narrows it, and abdominal fat reduces lung volume in a way that makes the airway less able to stay open — so losing weight acts on the mechanism directly rather than on a symptom.

This relationship was quantified long before these drugs. Older longitudinal work found that a 10% change in weight predicted a substantial change in apnea severity in both directions. What is new is that a 15–20% loss is now routinely achievable.

Improvement is not cure

This is where I would push back on some of the coverage.

Weight is one contributor. Craniofacial anatomy, tongue size, airway shape, age, nasal obstruction and alcohol all matter, and none of them respond to a GLP-1. A proportion of people with substantial weight loss still have clinically significant apnea — sometimes mild rather than severe, and still worth treating.

So the honest expectation is meaningful improvement with a genuine possibility of no longer needing treatment. Not a guarantee, and not something to assume on the basis of feeling better.

The trap: your CPAP settings are now wrong

Here is the practical failure I see most.

Required CPAP pressure correlates with weight. Lose 15–20% and the pressure titrated at your starting weight is frequently too high. Too much pressure is not benign — it produces air leak, aerophagia (swallowing air, which on a drug that already causes bloating is genuinely unpleasant), dry mouth, and a mask that feels like it is fighting you.

What people then do is entirely understandable and entirely wrong: they conclude the machine no longer suits them, use it less, and eventually stop.

The correct move is to tell your sleep service that your weight has changed substantially and ask for re-titration or a repeat study. Auto-titrating machines adjust within their set range, and the range, the mask size and the fit should all still be reviewed — mask fit changes with facial fat loss, which is the same process behind the facial changes discussed in the Ozempic face piece.

Do not stop CPAP unilaterally. Untreated apnea brings back the fragmented sleep, the daytime sleepiness, and the cardiovascular risk that treating it was meant to reduce.

If you have not been tested

A lot of people carry undiagnosed obstructive sleep apnea, and the symptoms are easy to attribute to something else — particularly on a drug that is changing your sleep anyway.

Worth asking for a sleep study if you have:

• Daytime sleepiness rather than difficulty falling asleep
• Waking unrefreshed after adequate hours
• Snoring, or a partner reporting pauses in breathing
• Morning headaches
• Nocturia — waking repeatedly to pass urine
• Poorly controlled blood pressure despite treatment

The distinction between sleepiness and insomnia is the useful one, and it is the same one drawn in the sleep supplement rankings — magnesium does nothing for an airway that closes.

The insurance angle

Worth naming plainly. An approved indication with a randomised trial behind it is a materially stronger basis for coverage than a request framed around weight alone.

If you have documented moderate-to-severe obstructive sleep apnea and obesity, that is a specific, coded, evidence-backed indication, and it belongs in the appeal — the same logic that runs through the denial section of what a GLP-1 actually costs.

What to do, in order

1. Get tested if you have symptoms and never have been.
2. Keep using CPAP while you lose weight, even as you start feeling better.
3. Tell your sleep service once you are down 10% or more.
4. Ask for re-titration or a repeat study rather than adjusting anything yourself.
5. Expect the mask to need refitting, because your face has changed shape.
6. Do not treat feeling better as evidence — apnea is defined by what happens while you are unconscious, which is exactly the state in which you cannot assess it.

And keep the resistance training going. Weight lost as muscle does nothing for your airway and costs you elsewhere, which is the argument in muscle is the whole game.